Executive Summary
A TAVI-first strategy for patients with concomitant severe aortic stenosis and coronary disease is noninferior to PCI-first at one year, per the TAVI PCI trial in NEJM, giving operators procedural flexibility but not settling whether the coronaries need fixing at all. A call-for-caution review in the Annals of Thoracic Surgery from Sousa Uva, Kaul and colleagues flags durability and reintervention signals in Evolut Low Risk 6-7 year and PARTNER 2A 10-year data, and a 13-study propensity-matched meta-analysis in Heart Lung & Circulation shows ViV-TAVR beats redo-SAVR on short-term mortality but leaves higher residual gradients — tightening the case for individualized, lifetime-management-aware Heart Team decisions rather than reflexive transcatheter expansion in younger patients.
- TAVI PCI (N=986, median age 82) hit noninferiority for the 1-year composite (22.2% vs 24.2%), and TAVI-first patients underwent fewer subsequent PCIs (NEJM via TCTMD).
- Real-world SAVR+CABG vs TAVR+PCI in 4,966 matched patients: TAVR+PCI wins at 30 days on mortality and stroke but SAVR+CABG wins at 3 years (18.7% vs 26.2% mortality) (Cardiovasc Revasc Med).
- Among 37,000+ US TAVR patients, 57% carried an HF diagnosis yet SGLT2i (3.4%) and MRA (8.4%) uptake post-TAVR remained abysmal (J Cardiovasc Med).
- Emboliner cerebral embolic protection secured FDA 510(k) clearance for TAVR, expanding the CEP market beyond Sentinel (Medical Device Network).
- Residual pulmonary hypertension after M-TEER (54% of 184 patients) tripled 2-year death/HF hospitalization risk, with pre-capillary and combined phenotypes driving the signal (Cardiovasc Interv Ther).
What to watch: The COMPLETE TAVR trial results will settle whether routine PCI — regardless of timing — beats medical management for CAD in TAVI patients, potentially rendering the TAVI-first vs PCI-first debate moot.
Aortic Valve (TAVR/TAVI)
The durability question is back on the table, this time from a surgical-led review team. Sousa Uva, Kaul, De Caterina and colleagues in the Annals of Thoracic Surgery integrate Evolut Low Risk 6-7 year, PARTNER 3 7-year, PARTNER 2A 10-year, and UK-TAVI data to argue TAVI's early treatment effect erodes with time — later mortality accrual, more MI, higher reintervention rates — and call for restraint in low-risk expansion. [NOTABLE] This aligns with ACC/AHA 2020 keeping SAVR as Class I for patients under 65 and directly challenges ESC 2025's more permissive TAVI-at-70 threshold. TAVI PCI (NEJM) gives operators sequencing freedom for concomitant CAD, but the median age of 82 limits generalizability to the younger patients now being offered TAVI under ESC guidance — the population where durability risk is most consequential. On residual risk: a Turkish 419-patient TAVI cohort found MCF ≤24% predicted 1-year cardiac death (18.7% vs 2.5%), and a TSI inflammatory-metabolic index study flagged higher mortality in reduced-LVEF TAVR patients — both single-center, retrospective, hypothesis-generating only. The RE-ACCESS 2 4D-CT substudy confirmed self-expanding THVs deform dynamically across the cardiac cycle (Acurate Neo2 > Evolut), with durability implications that remain unquantified.
Mitral Valve (MitraClip, PASCAL, TMVR)
Residual pulmonary hypertension after M-TEER is a stronger prognostic signal than current selection criteria capture. A 184-patient invasive hemodynamics study found 46% of patients had residual PH after clip, and pre-capillary (aHR 3.83) and combined pre/post-capillary phenotypes (aHR 3.60) drove death and HF rehospitalization at 2 years — isolated post-capillary PH did not. The ESC 2025 Class I recommendation for TEER in ventricular SMR under COAPT criteria caps SPAP at 70 mmHg but does not stratify by PH phenotype; this data exposes that gap, and the ACC/AHA 2020 Class IIa framing looks better calibrated to the residual uncertainty. Surgical MV repair, the ACC/AHA 2020 Class I standard for operable symptomatic primary MR, carries no equivalent phenotype-specific PH hazard in this context — the comparison is indirect but relevant when counseling borderline candidates. On the safety side, a Catheterization and Cardiovascular Interventions case report describes the first fully percutaneous retrieval of an embolized MitraClip from the subclavian artery — a reminder that single-leaflet device attachment occurs in up to 5% of cases and full embolization, while rare, has historically required vascular cutdown. A PASCAL case report in EHJ Case Reports illustrates the device's spacer advantage in borderline anatomy (baseline MVA 2.7 cm², final gradient 4.5 mmHg), but N=1 does not move the field.
Tricuspid Valve (TriClip, TTVR)
No new tricuspid-specific evidence today. The guideline gap here is the widest in structural heart: ESC 2025 elevated transcatheter TV treatment to Class IIa (LOE A) based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II, while ACC/AHA 2020 carries no recommendation at all. Extended follow-up from TRILUMINATE and additional TRISCEND II subgroup analyses on pacemaker and bleeding tradeoffs are the next data drops that will determine whether real-world enthusiasm closes or widens that gap.
Surgical vs. Transcatheter Comparisons
Two head-to-head datasets today, both cautionary for the transcatheter case. TriNetX propensity-matched analysis of 4,966 patients with AS+CAD showed TAVR+PCI wins at 30 days (mortality 2.7% vs 4.2%, stroke 3.8% vs 5.5%) but SAVR+CABG delivers superior 3-year survival (81.3% vs 73.8%). Real-world, retrospective, unmeasured confounding is substantial — but the crossover pattern is consistent with pivotal RCT long-term follow-up data. ACC/AHA 2020 recommends SAVR+CABG as Class I for patients with severe CAD requiring revascularization alongside valve intervention in lower-risk patients; the 3-year mortality gap here supports that position. A 13-study, 16,223-patient propensity-matched meta-analysis of ViV-TAVR vs redo-SAVR found ViV-TAVR halves short-term mortality (RR 0.47) and cuts bleeding, AKI, and length of stay — but residual gradients are significantly higher (SMD 0.45) and long-term mortality equalizes. This directly informs the lifetime management discussion ESC 2025 prioritized: TAV-in-SAV carries patient-prosthesis mismatch and residual gradient burden that must be planned for at the index procedure. Neither guideline currently offers strong ViV-specific direction beyond individualized Heart Team decision-making — a gap the field needs to close.
Device & Technology
The Emboliner cerebral embolic protection system received FDA 510(k) clearance for TAVR, entering a market where Boston Scientific's Sentinel has dominated despite ambiguous stroke-reduction data — PROTECTED TAVR showed no significant stroke reduction. Whether Emboliner's full-arch capture design translates to superior clinical outcomes is unproven. On pacing: a six-study meta-analysis (N=675) of conduction system pacing vs RV pacing post-TAVR showed CSP halved HF hospitalizations (RR 0.49) and shortened paced QRS by 31 ms, but mortality and LVEF were unchanged and implantation success was lower. Five of six studies were observational — this remains hypothesis-generating for the ~25% of TAVR patients requiring permanent pacing, not practice-changing. FDA also cleared the first AI-ECG model for acute MI detection.
Regulatory & Policy
Emboliner's 510(k) clearance (see Device section) is today's headline regulatory event. CEP for TAVR remains a 510(k) pathway — reflecting FDA's continued treatment of these devices as substantially equivalent rather than requiring pivotal RCT data, despite the ongoing clinical debate over meaningful stroke reduction. That regulatory posture deserves scrutiny given PROTECTED TAVR's null result.
Financial Analysis
Edwards Lifesciences drew multiple analyst notes this week questioning valuation at a 51x trailing P/E despite modest cash flow, per Simply Wall Street and MarketWatch. The forward P/E of 25.5 sits more reasonably against a TAVR growth story that today's Annals of Thoracic Surgery durability review directly threatens — if the surgical community successfully pushes back against low-risk TAVI expansion, EW's terminal growth assumptions get haircut. Boston Scientific's 36% six-month decline continues to weigh on the sector, and today's Emboliner clearance adds competitive pressure on the Sentinel CEP franchise. The TAVI PCI trial results are neutral-to-positive for Edwards given SAPIEN 3 Ultra dominance in the study cohort.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $86.18, -0.62% daily, +0.47% over 6 months
- Market cap $49.6B, trailing P/E 51.3, forward P/E 25.5, beta 0.85
- 52-week range $72.30-$96.29
- Analyst target $100.96 (buy consensus, 26 analysts)
- Next earnings 2026-10-29, EPS est $0.74, revenue est $1.68B
- Pure-play structural heart exposure means today's TAVR durability debate directly hits the thesis; TAVI PCI trial neutral-positive given SAPIEN dominance.
Medtronic (MDT)
- Close: $91.89, -0.54% daily, +3.99% over 6 months
- Market cap $117.5B, trailing P/E 22.6, forward P/E 14.4, beta 0.57
- 52-week range $73.31-$106.33
- Analyst target $104.76 (buy consensus, 25 analysts)
- Next earnings 2026-11-17, EPS est $1.39, revenue est $9.54B
- Evolut Low Risk 6-7 year signals from today's Annals review are the key overhang; diversified portfolio provides insulation EW lacks.
Abbott (ABT)
- Close: $105.23, -0.27% daily, -3.53% over 6 months
- Market cap $183.3B, trailing P/E 34.1, forward P/E 17.4, beta 0.59
- 52-week range $81.97-$137.49
- Analyst target $120.21 (buy consensus, 24 analysts)
- Next earnings 2026-10-14, EPS est $1.42, revenue est $12.99B
- MitraClip franchise benefits from ESC 2025 Class I for ventricular SMR TEER, though today's residual PH data adds selection nuance.
Boston Scientific (BSX)
- Close: $44.96, -0.04% daily, -35.73% over 6 months
- Market cap $65.2B, trailing P/E 18.2, forward P/E 13.1, beta 0.57
- 52-week range $42.20-$105.72
- Analyst target $62.69 (buy consensus, 29 analysts)
- Next earnings 2026-10-28, EPS est $0.81, revenue est $5.26B
- Emboliner FDA clearance today adds competitive pressure on Sentinel CEP franchise; six-month drawdown reflects broader concerns beyond structural heart.
Anteris Technologies (AVR.AX)
- Close: A$11.61, -1.53% daily, +35.16% over 6 months
- Market cap A$1.1B, forward P/E -5.4
- 52-week range A$5.20-$15.47
- Analyst target A$13.00 (single analyst)
- DurAVR THV progressing but still early-stage; small-cap volatility.
JenaValve Technology, J Valve Technology, and Meril Life Sciences are private (no public stock data).
Market outlook: Today's durability call-for-caution from a surgical-led author group in Annals of Thoracic Surgery is exactly the kind of narrative shift that pressures TAVR-dependent multiples. Watch whether this filters into ACC/AHA's next update — the ESC 2025 age-70 threshold looks increasingly out of step with the emerging long-term data.
Clinical Trial Updates
Aortic:
- NCT07813273 — ACCESS-FX+ Registry: Coronary access after Evolut FX Plus TAVI, impact of commissural alignment and large-cell frame design. Not yet recruiting, N=122, sponsored by Yonsei University. Directly relevant to today's lifetime management themes — Evolut FX Plus commissural alignment is a key selling point for future coronary access and TAV-in-TAV feasibility.
Mitral Repair:
- [LANDMARK] NCT05051033 — PRIMARY: Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 year-olds. Active, not recruiting, N=450, PI Annetine Gelijns. The head-to-head TEER vs surgical repair trial the field needs — will directly inform whether ACC/AHA's Class IIa TEER threshold for primary MR should shift. Now enrolled and in follow-up.
- NCT07380932: Catheter ablation for AF in patients with severe MR after successful transcatheter mitral valve repair. Not yet recruiting, N=956, sponsored by Atrial Fibrillation Network. Addresses the atrial secondary MR management pathway newly formalized in ESC 2025.
Tomorrow's watch: COMPLETE TAVR read-out remains the most consequential pending trial for the AS+CAD population addressed by today's TAVI PCI results — a null finding for routine PCI would fundamentally reshape how we approach the coronaries in TAVI candidates.